In this article

BABATWNKMRNAIMTX

Visitors at the Tesla booth at the World Artificial Intelligence Conference in Shanghai, July 6, 2023.
Costfoto | Nurphoto | Getty Images

Check out the companies making headlines in midday trading.

Teslaupgraded the stock to overweight from equal weight. Analyst Adam Jones said the firm is on the verge of a major leap in autonomous driving.

J.M. Smucker,Hostess buy Twinkies-maker Hostess Brands for $34.25 a share in a cash and stock transaction, valued at approximately $5.6 billion. hares of Hostess popped 19.1%, reaching a new 52-week high.

Tenable Holdings

Kenvueupgraded by Deutsche Bank to buy from hold on Sunday. The Wall Street firm called Kenvue a high-quality company and believes the stock’s slide has created an attractive entry point. The J&J spinoff has lost 15% since going public in May.

Alibabathe news that outgoing CEO Daniel Zhang would unexpectedly quit its cloud business. In June, the company had announced Zhang was leaving as chairman and CEO of Alibaba Group to focus on the cloud intelligence unit.

MetaMeta is developing a new AI system as capable as OpenAI’s most advanced model, and more powerful than the one it released two months ago called Llama 2. According to the report, Meta is aiming to launch the product by next year.

Nubankupgraded Nubank to overweight from neutral. JPMorgan said in a note to clients that Nubank should continue to gain market share in Brazil for multiple years and is trading at a “good entry point” after a recent stock price decline.

QualcommApple with 5G modems for smartphones through 2026. The continued sales to Apple will boost Qualcomm’s handsets business, and could soften the blow of potentially losing a critical customer.

Media stocks — Shares of DisneyCharter Communicationsblackout fight between the two companies. Shares of media peers Warner Bros. DiscoveryParamount

AstraZeneca Reuters, the pullback comes after a Sunday report in the Mail saying Chief Executive Pascal Soriot privately discussed leaving the company as early as next year.

Modernait announced it is partnering with German drug developer Immatics to further cancer vaccine developments. Moderna will give Immatics $120 million in upfront cash as part of the deal.

— CNBC’s Alexander Harring, Samantha Subin, Yun Li, Jesse Pound, Michelle Fox and Tanaya Macheel contributed reporting

Read More